University of Texas Medical Branch, Galveston, TX, U.S.A.
Works
- People in the News
- BioLight Reports Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert
- Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder
- New Partnership Between Christiana Care’s Gene Editing Institute and NovellusDx Speeds Progress Toward Personalized Cancer Medicine
- Luye Life Sciences Expands Global Reach as New Boston R&D Center Opens
- BioDelivery Sciences Signs Exclusive Agreement with Purdue Pharma (Canada) for the Licensing and Distribution Rights of BELBUCA® in Canada
- The FDA Has Accepted an Orphan Designation Request for Use of Truveta Administered Intranasally Submitted by Axium Pharmaceuticals Inc.
- Defymed Is Developing ExOlin®, a New Insulin Delivery Device
- Diasome Pharmaceuticals, Inc., Receives Funding Led By Medicxi
- Icon Bioscience Announces FDA Acceptance of NDA Filing for DEXYCU, a Noval Drug Therapy for Treating Inflammation Associated with Cataract Surgery
- Combining Implantation of Glaukos iStent inject® Trabecular Micro-Bypass with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile, According to New Study
- Upon Closure of the Merger Transaction, Agrium and PotashCorp Will Become Nutrien
- NanoSphere Health Sciences Signs Binding Merger Agreement for 100% Acquisition by Corazon Gold Corp.
- Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- Achelios Therapeutics Concludes Successful Type C Meeting with FDA Regarding Its Lead Product, TOPOFEN™, for Prevention and Treatment of Migraine
- Ensysce Biosciences Inc. Attending NIH Conference: Cutting Edge Science Meeting Series to End the Opioid Crisis: Development of Safe, Effective, Non-Addictive Pain Treatments
- Scientifically Advanced Delivery Technology in Sleep Management Debuts at SLEEP 2017 with Clinical Data Showing REMfresh®, the First and Only Continuous Release and Absorption Melatonin, Helps Maintain Sleep for up to 7 Hours
- Aequus Pharmaceuticals and CDRD Announce Research Collaboration to Improve Cannabinoid-Based Therapeutics
- Vetter and Microdermics Enter into a Strategic Cooperation Agreement to Develop Innovative Microneedle Drug Delivery Systems
- BIOCORP Signs an Industrialization Contract with Virbac
- Liquidia Technologies Announces Positive Phase 1 Data for LIQ865, Sustained-Delivery PRINT® Formulation of Bupivacaine for Postsurgical Pain Relief
- Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy Product
- From the Editor: Please Come to Boston
- Nemaura Pharma Memspatch Addresses Diabetics Fear of Needle Puncture Pain
- Elixir Medical Corporation Announces Outstanding 5-Year Clinical Data for CE Mark-Approved DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System
- Svelte Medical Systems Announces Sustained Outstanding Outcomes in Clinical Studies
- Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience
- Cingulate Therapeutics Initiates First Human Clinical Trial
- CBSET Appoints Rami Tzafriri, Ph.D., as Director of Research and Innovation
- Noven Appoints Ralph Lipp, Ph.D., as Vice President and Chief Scientific Officer
- FDA Accepts Genentech’s Biologics License Application for Subcutaneous Formulation of Rituximab
- Windtree Therapeutics Preclinical Study Results Show Potential for KL4 Surfactant as Possible Medical Countermeasure to Radiation Exposure
- Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results for Thin-Strut DESolve™ Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
- Intec Pharma Granted Chinese Patent for Accordion Pill™ Carbidopa/Levodopa
- Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016
- Aralez Completes Acquisition of Toprol-XL® and Its Authorized Generic from AstraZeneca
- Mati Therapeutics Expands Intellectual Property Portfolio
- Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to Include New Combination Product for Pain and Nausea
- Ocular Therapeutix™ and Regeneron Enter into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases
- Plant-Made Biopharmaceuticals Target Dental Plaque, Gum Tissues
- Lupin and MonoSol Rx Announce Licensing Agreement for Multiple Pediatric-Focused Products
- Dicerna Prioritizes Resources to Advance GalXC™ Product Candidates
- Bristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher, Suono Bio
- Transdermal Delivery Solutions and ALZYN Announce License for HypoSpray® Delivery of Alzheimers Therapy
- Aphios to Develop HIV/AIDS Cure Using Combination Drugs in Targeted “Nanosomes” Nanoparticles
- Catalent to Acquire Pharmatek, Adding Expanded Drug Development Services and Spray Drying Technology
- Wallace K. Reams, Former President of Aveva Drug Delivery Systems, Joins Transdermal Delivery Solutions Board of Advisors
- Chrono Therapeutics Raises $47.6 Million in Series B Financing to Advance Its Clinical Platform for Personalized Drug Therapy
- Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek® 2016
- DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer
- Crescita Therapeutics™ Inc. Announces Acquisition of INTEGA Skin Sciences
- Caisson Biotech Seeks Buyer for HEPtune® Drug-Delivery Platform
- NLS Pharma Announces Start of Its Phase 2 Trial for Mazindol in Adult ADHD Patients
- Egalet Announces Scientific Presentations at PAINWeek 2016 Meeting
- Mayne Pharma Acquires Rights to a Portfolio of Dermatology Foam Products Including Fabior® and Sorilux®
- Juniper Pharmaceuticals Reports Results from Phase 2b Clinical Trial of COL-1077 Lidocaine Vaginal Gel in Gynecologic Procedure Pain
- Oculis Completes Series A Financing
- Nemaura Pharma Limited Awarded the Prestigious 2016 Frost & Sullivan Award for Best Practices in Enabling Technology Leadership in Transdermal Drug Delivery
- TARIS Biomedical® Launches Second Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Bladder Cancer
- Heron Therapeutics Announces U.S. FDA Approval of SUSTOL® (Granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
- Intec Pharma to Pursue Development of Accordion Pill for Cannabinoid Therapies
- Frost & Sullivan Applauds IFP’s Superior Technology Performance and Best Practices in Providing Tailored, ApplicationSpecific Encapsulated Food Ingredients
- Wolfe Laboratories Addresses Rapid Growth with Executive Appointment
- Shasqi Local Drug Activation Technology Provides Improved Drug Efficacy with Minimal Side Effects
- Lannett Announces Receipt of FDA Acceptable Filing Letter for Fentanyl Patch ANDA
- STENTYS Enrolls First Patient in Left Main Clinical Trial
- AngioSoma’s Corporate Focus
- TARIS Biomedical® Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Muscle-Invasive Bladder Cancer
- Aphios Awarded Subcontract for Nanoformulation of Superhydrophobic Anticancer Drug
- SwRI, UTSA Invest in Two New Joint Biomaterial Research Projects
- Transdermal Delivery Solutions and MHC Medical Products Announce License for Penetran Plus® Topical Pain Reliever
- Gecko Biomedical Receives 1.4 Million Euros in Interest-Free Loan from Bpifrance to Advance Its Bio-Inspired Surgical Adhesive Solutions
- New Preclinical Data Show Potential of Dicerna GalXC™ Subcutaneous Delivery Platform as RNAi Drug Discovery Engine
- Acorda Presents Phase 1 Data on CVT-427 for Acute Treatment of Migraine at 58th Annual Scientific Meeting of the American Headache Society
- Highland Therapeutics Announces Positive Data from Second Pivotal ADHD Trial for HLD-200
- $1.8 Million Fast-Track NIH SBIR Grant for Manocept™ Immunotherapeutics Evaluation in Kaposi’s Sarcoma Awarded to Navidea
- Nanologica and Alcyone Lifesciences to Collaborate via Licensing Agreement
- NLS Pharma Announces Submission of Investigational New Drug (IND) Application to FDA for Its Controlled-Release Mazindol for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
